DRUG CANDIDATE DEVELOPED
CQ-001- CANNABIDIOL + PROPRIETARY API COMPOSITION
- Pre-clinical trials (rats) demonstrated positive anxiolytic effects and an improvement in the process of forming and storing memories, specifically those related to fear
- Suggests potential benefits for conditions such as anxiety, depression, and PTSD
- Predicted mechanism of action suggests synergistic effects at targets of interest, suggesting improved efficacy
- CQ-001 demonstrated a 35% increase in potency compared to isolated cannabidiol alone in a pre-clinical MES model of epilepsy (mice)
- Positioned to submit New Drug Applications (NDAs) for Phase II/III clinical trials to Health Canada & US FDA
- Approval is projected ∼ 2 & ∼ 3 years, respectively
SCIENTIFIC TEAM ESTABLISHED
Expertise in cannabinoids as therapeutics for epilepsy — team helped launch the only FDA-approved cannabidiol medication (Epidiolex®)
 |
“After examining CanaQuest’s portfolio, I recognize the opportunity for CQ-001 to build on the successes of previously approved CBD-based medications. With its combination of active compounds, preliminary data suggests that CQ-001 may offer enhanced benefits by targeting multiple mechanisms of action beyond those of CBD alone.”
Dr. Jordyn Stuart | Acting Chief Scientific Officer |
 |
“Our CBD-based formulation suggests a synergistic effect, demonstrating multiple times the efficacy compared to products containing isolated CBD on the market. This discovery indicates the potential for significantly smaller dosages of CBD to achieve the desired results without the associated negative side effects” |
 |
 |
Clinical Study: Neeka and the NHLAA are finalizing the protocols for former NHL hockey players
- Data to be used to support registration of Mentanine™ as a Natural Health Product in Canada
- Revenue stream to support further clinical drug development (precedent set by Big Pharma)
- Data generated for preliminary safety and efficacy signals of future pipeline indications.